Will Eurofins Scientific stock go up?

According to Danelfin AI, Eurofins Scientific has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (47.94%) is -1.75% vs. the average probability (49.69%) of all European stocks.

Is it a good time to buy, sell, or hold Eurofins Scientific stock right now?

Eurofins Scientific has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (47.94%) is -1.75% vs. the average probability (49.69%) of all European stocks, based on our AI-powered analysis. You can find more details on whether Eurofins Scientific stock is a good buy .

What is going on with Eurofins Scientific stock in the last 3 months?

The Eurofins Scientific stock performance in the last quarter has been +2.07%.

Does Eurofins Scientific offer dividend payments?

Yes, Eurofins Scientific stock dividend yield is 1.05%.

What is the current market capitalization of Eurofins Scientific?

Eurofins Scientific's market cap is €12.07B, as of 2026-07-02 08:00.

Eurofins Scientific SE (ERF.PA) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

ERF.PA AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Eurofins Scientific SE today receives an AI Score of 4/10, which translates to a Hold rating. The stock has a 48% probability of outperforming the market in the next 3 months, which is 2% lower than the average probability of any stock (50%). This lower probability is driven by several key detractors. The most significant negative influence is the company's Life Sciences Tools & Services industry, which detracts -4.17% from the probability. Other notable detractors include its bottom 40% ranking in Avg. Last Decile Drawdown (1Y) (-0.97%) and a top 10% ranking in Receivable Turnover YoY Growth, which paradoxically has a negative impact (-0.62%). On the positive side, the stock is boosted by strong fundamentals, including a top 10% ranking in Diluted EPS (+0.78%) and a top 10% ranking in Consolidated Net Income / Loss (+0.70%). Notable data points that shape this outlook include the company's robust profitability metrics, with Diluted EPS and Consolidated Net Income both in the top 10%. However, this strength is offset by significant headwinds from its sector classification and risk profile, as seen in its bottom 40% ranking for average drawdown in the worst-performing decile. The current market sentiment, as measured by the Fear & Greed Index at a value of 31, provides a modest positive influence (+0.55%). The aggregated impact of numerous other fundamental and technical signals, represented by the Long Tail factors, also adds to the probability. The overall picture is one of a company with solid financials weighed down by industry and risk factors, resulting in a slightly below-average probability of market outperformance and a Hold rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Profitability+1.21%
Profitability and operating efficiency metrics
Growth+0.78%
Expected pace of revenue and earnings expansion
Valuation+0.50%
How the stock is priced relative to its fundamentals
Size & Liquidity+0.44%
Company size and trading liquidity
Earnings Quality+0.33%
Stability and reliability of reported earnings
Financial Strength+0.01%
Balance sheet strength and financial resilience

Sentiment-3.30%
How analysts and the market view the stock
Volatility-1.19%
How much the stock price tends to fluctuate
Momentum-0.53%
Direction and strength of recent price movements

ERF.PA probability advantage of beating the market (3M):

-1.75%

AI Score

Hold

Eurofins Scientific (ERF.PA) has an AI Score of 4/10 (Hold) because, according to an overall analysis, it has a probability advantage of -1.75% of beating the market (STOXX 600) in the next 3 months. This advantage is calculated as the difference between the average probability of any European stock (49.69%) and the probability of ERF.PA (47.94%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any European stock of beating the market (3M)49.69%
ERF.PA probability advantage of beating the market (3M)-1.75%
ERF.PA probability of beating the market (3M)47.94%

ERF.PA probability advantage of beating the market (3M): -1.75%

The AI-powered overall analysis of Eurofins Scientific (ERF.PA) is based on the 33 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 24 months (alpha signals). These alpha signals explain the probability advantage of ERF.PA:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Life Sciences Tools & Services	N/A	-4.17%
Technical	Avg. Last Decile Drawdown (1Y)	-0.06		-0.97%
Fundamental	Diluted EPS	2.54		+0.78%
Technical	Chart Pattern (504d)	figure_3	N/A	+0.77%
Fundamental	Consolidated Net Income / Loss	473M		+0.70%
Fundamental	Receivable Turnover YoY Growth	1.14%		-0.62%
Sentiment	Fear & Greed Index (CNN)	31	N/A	+0.55%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+0.50%
Fundamental	Gross Income YoY Growth	1.16%		+0.49%
Fundamental	Provision For Income Taxes YoY Growth	1.41%		+0.44%
Fundamental	Upgrade to unlock			+0.44%
Technical	Upgrade to unlock			-0.38%
Technical	Upgrade to unlock			-0.35%
Technical	Upgrade to unlock			+0.28%
Technical	Upgrade to unlock			-0.28%

Rest of Alpha Signals: +0.04%

ERF.PA probability advantage of beating the market (3M)Total:-1.75%
ERF.PA AI Score

Significant changes Vs previous day

ERF.PA Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:€68.29
Horizon: 3 months
Stop Loss:€XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:€XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

ERF.PA Proven Hold Signal & Price Forecast

This is the price chart for ERF.PA from January 1, 2026 until today. The chart indicates, in yellow, the 117 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

ERF.PA Average Past Performance & Win Rate

Three months after its 1058 Hold signals since July 2026, ERF.PA had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

1058 Past ERF.PA Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+2.59%
Average Alpha				+10.89%
Win Rate (% Positive Perf.)				36.73%
% Positive Alpha				78.75%

ERF.PA Frequently Asked Questions

Will Eurofins Scientific stock go up?
According to Danelfin AI, Eurofins Scientific has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (47.94%) is -1.75% vs. the average probability (49.69%) of all European stocks.
Is it a good time to buy, sell, or hold Eurofins Scientific stock right now?
What is going on with Eurofins Scientific stock in the last 3 months?
Does Eurofins Scientific offer dividend payments?
What is the current market capitalization of Eurofins Scientific?

Eurofins Scientific SE Company Profile

Eurofins Scientific SE (ERF.PA) provides a broad portfolio of laboratory testing and analytical services. It serves clients across various sectors, including pharmaceuticals, food, environment, and consumer products. The company's services support product development, quality control, and regulatory compliance globally.

The company offers extensive food and feed testing services. These services ensure the safety, quality, and authenticity of food products throughout the supply chain. They include detailed analysis for contaminants such as pesticides, heavy metals, mycotoxins, and veterinary drug residues. Eurofins also performs allergen detection, nutritional analysis, and microbiological testing to identify pathogens. These comprehensive services help manufacturers meet stringent regulatory standards and consumer expectations for product integrity.

Eurofins provides comprehensive environmental testing solutions. These services analyze water, air, soil, and waste samples for a wide array of pollutants and hazardous substances. The company supports industrial and governmental clients with environmental monitoring, site assessment, and regulatory compliance. Furthermore, it delivers a wide range of pharmaceutical and biopharmaceutical services. These include support for drug discovery, preclinical and clinical trial testing, and quality control for manufacturing processes. Services cover bioanalytical testing, product release testing, and stability studies for new and existing drugs.

The company's agroscience services support the development and registration of crop protection products and seeds. This involves conducting field and laboratory studies for efficacy, residue analysis, and environmental impact assessments. Eurofins also performs testing for a variety of consumer products. These include cosmetics, textiles, toys, electronics, and detergents. Such testing verifies product safety, performance characteristics, and compliance with international and national standards.

Eurofins serves a diverse global client base, encompassing enterprises in the pharmaceutical, food, environmental, and consumer goods industries, as well as public sector organizations. The company generates revenue primarily from fees for its extensive portfolio of laboratory and analytical services, operating globally through direct sales channels.

Sector:Health Care
Country:-
Industry:
Address:23 Val Fleuri, Luxembourg
Employees:65,694
Website:eurofins.com

Pros

High client switching costs in specialized testing

Favorable regulatory environment driving demand

Consolidation opportunities in a fragmented market

Diversified service portfolio across multiple industries

Global laboratory network offering scale efficiencies

Cons

Capital expenditure requirements for laboratory equipment

Pricing pressure from large volume customers

Reliance on specialized scientific talent acquisition

Operational complexities from frequent laboratory acquisitions

Demand sensitivity to client research and development budgets

Pros

Cons

Company	AI Score	Compare
ALECR.PAEurofins Cerep SA

Company

AI Score

Compare

ALECR.PAEurofins Cerep SA

Company

AI Score

Compare

ERF.PA Top 10 Industry Stocks

Life Sciences Tools & Services

	Company	AI Score	Compare
1	PANG.MCPangaea Oncology SA
2	SFZN.SWSiegfried Holding AG
3	DXRX.LDiaceutics PLC
4	ERF.PAEurofins Scientific SE
5	DIM.PASartorius Stedim Biotech SA
6	BANB.SWBachem Holding AG
7	MLC.IRMalin Corporation PLC
8	CHEMM.COChemometec A/S
9	GUBRA.COGubra A/S
10	HEN.WA

	Company	AI Score	Compare

ERF.PA Top 10 Sector Stocks

Health Care

	Company	AI Score	Compare
1	REC.MIRecordati Industria Chimica e Farmaceutica SpA
2	FAE.MCFaes Farma SA
3	ALK B.COALK-Abello A/S
4	ANCR.LAnimalcare Group plc
5	LKMNH.E.ISLokman Hekim Engurusag Saglik Turizm Egitim Hizmetleri ve Insaat Taahhut AS
6	LAB.MCLabiana Health SA
7	TNZTP.E.ISTapdi Oksijen Ozel Saglik ve Egitim Hizmetleri Sanayi Ticaret AS
8	MPARK.E.ISMLP Saglik Hizmetleri AS
9	PRM.MCPrim SA
10	AEVS.SWAevis Victoria SA

	Company	AI Score	Compare

ERF.PA Stock AI Analysis